Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
AstraZeneca PLC's quarterly P/E stands at 59.3x, down 12.4% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 18.6% YoY to 31.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 63.75 | 59.29 | 46.14 | 43.73 | 39.22 | 67.71 | 83.95 | 63.01 | 48.91 | 108.43 | 76.73 | 60.97 | 60.41 |
| — | -12.4% | -45.0% | -30.6% | -19.8% | -37.6% | +9.4% | +3.3% | -19.0% | -7.7% | +51.9% | -77.3% | -76.7% | |
| P/S Ratio | 5.50 | 8.84 | 7.68 | 7.45 | 8.47 | 6.82 | 8.88 | 9.42 | 8.43 | 8.73 | 9.17 | 9.83 | 10.05 |
| — | +29.7% | -13.5% | -20.9% | +0.5% | -21.9% | -3.1% | -4.2% | -16.2% | -7.9% | +20.6% | +5.3% | +8.9% | |
| P/B Ratio | 13.37 | 11.25 | 10.15 | 9.61 | 11.19 | 9.94 | 11.81 | 12.31 | 11.39 | 10.72 | 11.32 | 12.00 | 12.21 |
| — | +13.3% | -14.0% | -21.9% | -1.8% | -7.3% | +4.3% | +2.6% | -6.7% | -6.5% | +19.2% | +7.3% | +5.6% | |
| P/FCF | 27.47 | 104.95 | 26.23 | 73.62 | 35.05 | 52.01 | 59.50 | 50.43 | 121.26 | 73.18 | 47.13 | 90.88 | 65.74 |
| — | +101.8% | -55.9% | +46.0% | -71.1% | -28.9% | +26.2% | -44.5% | +84.5% | +27.1% | +2.7% | -36.3% | +79.5% | |
| EV / EBITDA | 17.82 | 31.87 | 23.93 | 23.31 | 24.55 | 39.16 | 32.42 | 31.94 | 25.97 | 43.20 | 34.38 | 31.69 | 28.55 |
| — | -18.6% | -26.2% | -27.0% | -5.5% | -9.4% | -5.7% | +0.8% | -9.0% | -9.4% | -1.1% | -43.7% | -44.0% | |
| EV / EBIT | 25.26 | 46.13 | 33.39 | 32.01 | 32.45 | 51.40 | 55.65 | 45.26 | 35.33 | 82.44 | 54.44 | 46.96 | 44.02 |
| — | -10.2% | -40.0% | -29.3% | -8.1% | -37.6% | +2.2% | -3.6% | -19.7% | -17.4% | -23.5% | -75.4% | -64.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
AstraZeneca PLC's operating margin was 19.2% in Q4 2025, down 4.4 pp QoQ and up 5.5 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 23.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.9% | 79.9% | 81.6% | 82.9% | 83.5% | 81.7% | 77.3% | 83.1% | 82.5% | 80.8% | 81.8% | 82.8% | 82.5% |
| — | -2.2% | +5.5% | -0.3% | +1.2% | +1.1% | -5.5% | +0.4% | +0.0% | +9.0% | +12.2% | +14.8% | +19.2% | |
| Operating Margin | 23.4% | 19.2% | 23.6% | 24.3% | 27.0% | 13.7% | 15.5% | 21.2% | 24.6% | 10.3% | 17.0% | 21.5% | 23.4% |
| — | +40.5% | +51.9% | +14.3% | +10.1% | +33.2% | -8.7% | -1.3% | +4.9% | +5.1% | +50.0% | +329.9% | +204.0% | |
| Net Margin | 17.5% | 15.0% | 16.7% | 16.9% | 21.5% | 10.1% | 10.5% | 14.9% | 17.2% | 8.0% | 12.0% | 15.9% | 16.6% |
| — | +48.9% | +58.3% | +13.8% | +24.9% | +26.2% | -11.9% | -6.5% | +3.7% | -0.7% | -19.9% | +376.5% | +389.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | 4.9% | 5.6% | 5.7% | 7.1% | 3.7% | 3.6% | 5.0% | 5.7% | 2.5% | 3.7% | 5.0% | 4.9% |
| — | +33.8% | +57.0% | +14.1% | +25.1% | +46.1% | -3.5% | +0.7% | +14.9% | +0.7% | -20.2% | +398.7% | +384.9% | |
| ROA | 9.4% | 2.0% | 2.2% | 2.2% | 2.8% | 1.4% | 1.4% | 1.9% | 2.1% | 1.0% | 1.4% | 1.9% | 1.9% |
| — | +41.8% | +63.5% | +20.1% | +29.4% | +47.5% | -4.3% | -0.9% | +14.8% | +3.0% | -17.0% | +414.4% | +397.3% | |
| ROIC | 14.9% | 3.1% | 3.8% | 3.8% | 4.1% | 2.3% | 2.4% | 3.2% | 3.7% | 1.5% | 2.4% | 3.0% | 3.2% |
| — | +35.9% | +61.3% | +20.6% | +11.8% | +52.4% | -1.3% | +5.2% | +17.4% | +10.3% | +54.6% | +354.5% | +200.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
AstraZeneca PLC's Debt/EBITDA ratio is 6.6x, up from 6.4x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.61 | 0.61 | 0.71 | 0.73 | 0.77 | 0.74 | 0.77 | 0.85 | 0.92 | 0.73 | 0.77 | 0.80 | 0.88 |
| — | -17.3% | -8.1% | -13.5% | -16.3% | +0.8% | +0.7% | +6.2% | +4.7% | -7.4% | -7.9% | -2.9% | +2.8% | |
| Debt / EBITDA | 1.53 | 6.62 | 6.36 | 6.71 | 6.40 | 10.95 | 8.05 | 8.33 | 7.91 | 11.18 | 8.83 | 8.00 | 7.78 |
| — | -39.6% | -20.9% | -19.5% | -19.1% | -2.0% | -8.9% | +4.2% | +1.7% | -10.2% | -22.3% | -48.7% | -45.3% | |
| Current Ratio | 0.94 | 0.94 | 0.88 | 0.86 | 0.90 | 0.93 | 0.93 | 0.89 | 0.89 | 0.82 | 0.79 | 0.87 | 0.90 |
| — | +1.2% | -5.6% | -2.9% | +1.3% | +13.0% | +18.4% | +2.7% | -1.1% | -4.5% | -3.3% | -9.7% | -10.1% | |
| Quick Ratio | 0.72 | 0.72 | 0.69 | 0.67 | 0.70 | 0.74 | 0.71 | 0.69 | 0.70 | 0.64 | 0.60 | 0.67 | 0.70 |
| — | -1.8% | -3.9% | -3.0% | -0.8% | +14.7% | +18.5% | +2.4% | +0.7% | -5.6% | -1.2% | +0.1% | +5.3% | |
| Interest Coverage | 8.11 | 6.31 | 8.26 | 7.99 | 10.53 | 4.75 | 4.61 | 6.20 | 7.54 | 2.77 | 4.98 | 5.70 | 6.98 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonAstraZeneca PLC's current P/E is 63.7x. The average P/E over the last 4 quarters is 47.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AstraZeneca PLC's current operating margin is 23.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AstraZeneca PLC's business trajectory between earnings reports.